Comment on: Dual advanced therapy in inflammatory bowel disease. Why, when and how?

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) presents management challenges, particularly with extraintestinal manifestations or co-occurring immune-mediated diseases.
• Current therapeutic options may be insufficient for a subset of IBD patients requiring advanced treatment strategies.

Purpose of the Study:

• To introduce dual targeted therapy as a novel treatment approach for complex inflammatory bowel disease (IBD) cases.
• To highlight the potential of combining biological agents and small molecules for managing difficult-to-treat IBD.

Main Methods:

• Review of emerging therapeutic strategies in inflammatory bowel disease (IBD) management.
• Focus on combination therapies involving two distinct biological agents and/or small molecules.

Main Results:

• Dual targeted therapy is an emerging option for patients with refractory inflammatory bowel disease (IBD).
• This approach shows promise for IBD patients with extraintestinal manifestations or associated immune-mediated conditions.

Conclusions:

• Dual targeted therapy represents a potential advancement in the personalized management of inflammatory bowel disease (IBD).
• Prospective studies and randomized controlled trials are crucial to establish the definitive efficacy and safety profile of this therapeutic strategy.